What is the recommended dose and use of Meropenem (generic name) for treating bacterial infections, particularly in patients with impaired renal function?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 27, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Meropenem Dosing and Clinical Use

Standard Dosing in Normal Renal Function

For most serious bacterial infections in adults with normal renal function, administer meropenem 1 gram IV every 8 hours, or 500 mg every 8 hours for uncomplicated skin infections. 1

Adult Dosing by Indication

  • Complicated skin and skin structure infections (cSSSI): 500 mg IV every 8 hours 1
  • Complicated intra-abdominal infections: 1 gram IV every 8 hours 1
  • Infections caused by P. aeruginosa: 1 gram IV every 8 hours (higher dose required) 1
  • Carbapenem-resistant Enterobacteriaceae (CRE): 1 gram IV every 8 hours by extended infusion (3 hours) as part of combination therapy 2, 3
  • Carbapenem-resistant Acinetobacter baumannii (CRAB): 2 grams IV every 8 hours 4, 2

Administration Method

  • Standard infusion: 15-30 minutes for all doses 1
  • Bolus injection: 3-5 minutes for 1 gram doses (acceptable alternative) 1
  • Extended infusion: 3 hours when MIC ≥8 mg/L or treating CRE/CRAB 4, 2

Extended infusion over 3 hours is critical for optimizing pharmacodynamic targets when treating resistant organisms or when meropenem MIC is ≥8 mg/L for CRE or ≥32 mg/L for CRAB. 4


Dosing in Renal Impairment

Dose reduction is mandatory when creatinine clearance falls below 50 mL/min. 1

Renal Dosing Algorithm

Creatinine Clearance Dose Interval
>50 mL/min Standard dose (500 mg or 1 g) Every 8 hours
26-50 mL/min Standard dose Every 12 hours
10-25 mL/min Half the standard dose Every 12 hours
<10 mL/min Half the standard dose Every 24 hours

1

Important caveat: There is inadequate data for dosing in patients on hemodialysis or peritoneal dialysis—use extreme caution and consider infectious disease consultation. 1


Pediatric Dosing

Children ≥3 Months of Age with Normal Renal Function

Dose meropenem based on weight and infection type, with maximum doses capped at adult equivalents. 1

  • cSSSI: 10 mg/kg every 8 hours (max 500 mg per dose) 1
  • Complicated intra-abdominal infections: 20 mg/kg every 8 hours (max 1 gram per dose) 1
  • Meningitis: 40 mg/kg every 8 hours (max 2 grams per dose) 1
  • cSSSI caused by P. aeruginosa: 20 mg/kg every 8 hours (max 1 gram per dose) 1

For children >50 kg, use adult dosing. 1

Infants <3 Months of Age

Dosing depends on both gestational age (GA) and postnatal age (PNA), with all doses given as 30-minute infusions. 1

Gestational & Postnatal Age Dose Interval
<32 weeks GA, PNA <2 weeks 20 mg/kg Every 12 hours
<32 weeks GA, PNA ≥2 weeks 20 mg/kg Every 8 hours
≥32 weeks GA, PNA <2 weeks 20 mg/kg Every 8 hours
≥32 weeks GA, PNA ≥2 weeks 30 mg/kg Every 8 hours

1


Treatment Duration

For complicated intra-abdominal infections, treat for 5-7 days, individualized based on source control adequacy and clinical response. 2, 3

  • Discontinue within 24 hours if cholecystitis is limited to the gallbladder wall and cholecystectomy is performed 2
  • Duration should be guided by infection site, adequacy of source control, and clinical improvement 2, 3

Combination Therapy for Resistant Organisms

Carbapenem-Resistant Enterobacteriaceae (CRE)

Always use combination therapy—never meropenem monotherapy—when treating CRE infections. 2, 3

  • Requires extended 3-hour infusion 4, 2
  • Indicated when meropenem MIC ≤8 mg/L 4
  • Combine with at least one other active agent 4

Carbapenem-Resistant Acinetobacter baumannii (CRAB)

Consider high-dose extended-infusion meropenem (2 grams every 8 hours over 3 hours) as part of combination therapy when meropenem MIC ≤8 mg/L for CRAB pneumonia or bloodstream infections. 4

  • Polymyxin-meropenem combinations rank highest for clinical cure in CRAB pneumonia 4
  • For CRAB with meropenem MIC ≥32 mg/L, combination therapy with extended infusion is recommended 4
  • Colistin-carbapenem combinations showed 91.7% probability of improving clinical cure 4

Critical Clinical Considerations

Seizure Risk

High doses of meropenem (particularly >6 grams/day) are associated with increased seizure risk. 4

  • Monitor closely in patients with CNS disorders or renal impairment 4
  • Meropenem has lower seizure risk than imipenem 5, 6

No Loading Dose Required

Unlike colistin, tigecycline, or vancomycin, meropenem does not require a loading dose. 2

  • Optimization is achieved through extended infusion, not loading doses 2
  • Start with standard dosing immediately 2, 1

Spectrum Gaps

Meropenem is NOT effective against methicillin-resistant S. aureus (MRSA), vancomycin-resistant enterococci (VRE), or Stenotrophomonas maltophilia. 2, 5

  • Active against methicillin-susceptible S. aureus only 2, 1
  • Vancomycin-susceptible E. faecalis is covered, but not E. faecium 1, 7

Pharmacodynamic Target

Meropenem exhibits time-dependent bactericidal activity; the critical parameter is maintaining free-drug concentrations above the MIC for approximately 40% of the dosing interval (%T>MIC). 8

  • Extended infusions optimize this target for resistant organisms 8
  • Standard intermittent dosing is adequate for susceptible pathogens 8

Drug Compatibility Warning

Do not mix meropenem with other drugs in the same solution or infusion container. 1

  • Administer separately from other antimicrobials 1
  • Compatibility with other agents has not been established 1

References

Guideline

Meropenem for Complicated Bacterial Infections

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Meropenem Dosage and Treatment for Bacterial Infections

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Meropenem: evaluation of a new generation carbapenem.

International journal of antimicrobial agents, 1997

Research

Meropenem: a microbiological overview.

The Journal of antimicrobial chemotherapy, 1995

Research

Pharmacokinetic and pharmacodynamic properties of meropenem.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2008

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.